CNTLN

Across TCGA pan-cancer cohorts, CNTLN mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CNTLN data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CNTLN mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CNTLN expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, UCEC, and LUAD are the cancer types where CNTLN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.836	0.412	.003	50	view →
UCEC	OS	Quartile	II,III,IV	0.502	1.000	.028	16	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	13	view →
GBM	DFS	Tertile	All	0.504	0.232	.026	7	view →
PDAC	DFS	Tertile	All	0.595	1.000	.018	7	view →
CCRCC	OS	Median	All	0.298	1.000	.040	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CNTLN–HNSC (DFS)

Open the HNSC breakdown →